these highly heterogeneous patient populations into well-defined subgroups that share common molecular and immuno-pathophysiology profiles. By doing this, we are able to identify highly specific biomarkers and novel drug targets. We then use discovered endotypes, biomarkers, and drug targets to develop patient stratification, enrichment, and indication expansion strategies, early hits/leads for the therapeutic pipeline, and eventually complex theranostic products together with our biopharma and IVD partners.